Innovation as the key to GT Manufacturing

While gene therapy remains a relatively new therapeutic modality, expected improvements similar to those seen in the monoclonal antibody space have largely not occurred.  We will discuss the importance of continued innovations for viral vectors, concentrating on efforts made in Oxford Biomedica’s Lentivirus template process, as well as AAV productivity and purity results recently announced at the company’s newly formed Boston based company, Oxford Biomedica Solutions.